A B S T R A C T Four normal men were injected intravenously with physiological doses (6 ltg) of vitamin Ds-1,2-2H. Serial 
INTRODUCTION
Recent studies of vitamin D metabolism have demonstrated that vitamin D is rapidly converted into a more polar metabolite after its intravenous injection into humans (1) or other animals (2) (3) (4) . This metabolite, isolated from swine plasma, was identified as 25-hydroxycholecalciferol by Blunt, DeLuca, and Schnoes (3), and Limited information is available about the turnover and the plasma transport of vitamin D3 and of its 25-hydroxy metabolite. In 1967, Avioli, Lee, McDonald, Lund, and DeLuca reported that cholecalciferol-'H disappeared rapidly from the plasma of normal subjects with a halflife of 20-30 hr (1) . Coincident with the disappearance of cholecalciferol, a more polar metabolite with the properties of 25-hydroxycholecalciferol appeared. A slower plasma disappearance rate of vitamin D8-'H and a reduction in the amount of label appearing as the polar metabolite were observed in patients with vitamin D-resistant rickets (12) . More recently, Mawer, Lumb, and Stanbury reported that, after the initial rapid disappearance of labeled vitamin D8 from human plasma, a prolonged second phase was seen with a half-life of 20-44 days (13) . A large proportion of the radioactivity found in plasma during the slow second phase was present as polar metabolites. In this study the amounts of labeled vitamin D injected were 10-20 times the recommended daily allowance for vitamin D (14) .
Before the isolation and identification of 25-hydroxycholecalciferol, several studies were conducted to examine the transport of vitamin D in human (15) (16) (17) and in rat (18, 19) serum. Human serum proteins were separated by agar-gel electrophoresis by de Crousaz, Blanc, and Antener, who found vitamin D activity, by bioassay, in the albumin and ae-globulin fractions (16) . Thomas et al. also found vitamin D activity in-association with the a-globulin and albumin fractions of human serum ( 15) . Using labeled vitamin D3, Rikkers and DeLuca found that both the vitamin and its polar metabolite were associated with several protein bands, but particularly with an a-globulin, after disc gel electrophoresis (19) . No information is available about the plasma transport of 25-hydroxycholecalciferol in man.
We now report a study of the turnover of vitamin D3 and of its polar metabolite in humans after the administration of small, physiological doses of the labeled vitamin. The transport of the vitamin and particularly of its polar metabolite has been examined in some detail. Neither the vitamin nor its polar metabolite circulates in association with the known plasma lipoproteins. The transport protein for the polar metabolite has been partly characterized with regard to apparent molecular size and to electrophoretic mobility. 2Abbreviations used in this paper: BHT, butylated hydroxytoluene; RBP, retinol-binding protein; TLC, thin-layer chromatography; TMS, trimethylsilyl. mg of unlabeled carrier cholecalciferol' was added to each extraction. Each extraction mixture was split into two phases by addition of 5 volumes of 0.05% H2SO4, and the entire CHC13 phase was collected and evaporated to dryness under a stream of nitrogen. Portions of the total lipid extracts so obtained were assayed directly for radioactivity; other portions were subjected to column or thin-layer chromatography.
METHODS
Column chromatography was performed with amber glass columns of 1 cm diameter containing 5 g of silicic acid (Unisil, 100-200 mesh).' 11 fractions were eluted from each column in a stepwise procedure as shown in Table I . This elution scheme is a modification of the elution schemes employed in this laboratory for the separation of plasma neutral lipids and phospholipids (20, 21) . The scheme shown in Table I 25-hydroxycholecalciferol was added to the extraction mixture for each of these samples. The total lipid extract was suspended in 200 Al of a solution of pyridine-hexamethyldisilazane-trimethylchlorosilane, 9:3:1 (22) (Sil-prep)' and allowed to react for 60 min. Portions of the reaction mixtures were then subjected to TLC on silica gel plates in two different systems: (a) benzene-ethyl acetate, 3:1, and (b) two-directionally with benzene-hexane, 1: 1, followed at right angles by methyl ethyl ketone-acetonitrile, 7: 3, 80% saturated with mineral oil. The area of the carrier was located as described above, and the scraped bands or spots were eluted with hot benzene-ethyl ether, 1: 1.
Separation of lipoproteins. Plasma lipoproteins were separated from proteins with hydrated density greater than 1.21 by ultracentrifugation, using a simplified modification of the method of Havel, Eder, and Bragdon (23) . For each separation, 10 ml of fresh plasma was placed in a i X 3 in. plasma obtained from subject C. H. on the 15th day after injection; and (c) a pooled sample of plasma obtained from subject C. H. on the 5th, 27th, and 34th days of study.
Preparative polyacrylamide gel electrophoresis was performed with a Buchler9 "poly-prep 200" apparatus as described previously (24) .
Bioassay. The vitamin D activity of plasma and plasma fractions was estimated by the in vitro uptake of '5Ca by intestinal slices (25, 26) . The samples which were assayed included total lipid extracts of whole plasma and of the lipoprotein (d < 1.21) and d> 1.21 fractions of plasma. The cholecalciferol-containingand25-hydroxycholecalciferolcontaining fractions (fractions 3+4+5 and fraction 8, respectively) after silicic acid column chromatography of extracts of whole plasma were also bioassayed. Carrier vitamin D was not added at any time to these samples, and all organic solvents contained 1 mg BHT per 100 ml. The CHCl3 extracts or column fractions derived from 20 ml of plasma were concentrated under nitrogen to approximately 5 ml and transferred to a vial containing 1 g of olive oil with 0.1% BHT (w/w). The samples were flushed with nitrogen until the solvent was fully evaporated. The olive oil solutions and dilutions of USP reference vitamin D, were administered with calibrated dropping pipets to vitamin D-deficient rats. The rats were prepared by feeding rachitogenic diet No. 2 ' for 5 wk to weanling male rats of the Sherman strain" kept in covered cages. Each rat received two drops initially and three drops 12 hr later. The in vitro uptake studies were conducted 44-50 hr after giving the initial dose. The intestines were removed and incubated as described by Gordan and Schachter (26) except that 45Ca' was used instead of "Ca. The incubated intestinal slices (approximately 200 mg) were removed from the incubation medium, blotted dry, and homogenized with 2 ml of 1 Ai EDTA in a Potter-Elvehjem homogenizer. The homogenates were centrifuged at 12,000 g for 30 min, and 0.2 ml of the supernatant solutions each was suspended in 1 ml of 1 M hyamine hydroxide in methanol. After the suspensions became clear, 10 ml of the counting solution described by Bray (27) was added, and the vials were shaken intermittently until a gel formed. After standing overnight at room temperature, the samples were assayed for '5Ca in a Packard Tri-Carb liquid scintillation counter.
Other procedures. Radioassay for 8H was carried out by dissolving samples in 15 ml of 0.5%o diphenyloxazole in toluene followed by assay with a Packard liquid scintillation The half-life of the slow, semilogarithmic disappearance of radioactivity from plasma (see Results) was determined for each subject on the eight observations made between the 4th and 50th days after the injection of cholecalciferel-'H. For subject C. H. nine observations between the 7th and 56th days were used. Linear regression lines of the logarithm of the concentration of radioactivity vs. time in days were calculated by the method of least squares (28) , using a Wang' model 700 electronic calculator. The halflives were calculated from the regression lines. RESULTS Turnover of radioactive vitamin Ds. Fig. 1 shows the results obtained with the four subjects who were injected with 6 tg of cholecalciferol-2H. The semilogarithmic plot of the concentration of plasma total radioactivity vs. time described a curve during the first 4 days, whereas beyond this time the plot followed a straight line.
Extracts of each of the plasma samples collected in this study were analyzed by silicic acid column chromatography. In all samples, quantitatively significant amounts of 'H were only recovered in the cholecalciferolcontaining fractions (fraction 3 + 4 + 5) and in the 25-hydroxycholecalciferol-containing fraction (fraction 8 tion is available about the labeled compounds which were recovered in fraction 10.
During the early, curvilinear part of the plasma total radioactivity plot, labeled cholecalciferol disappeared rapidly from plasma, with an initial half-life, during the first 48 hr, of 12 hr (Fig. 1) . Cholecalciferol represented only 13% of the total plasma radioactivity after 48 hr and less than 1 % after 7 days in the four subjects receiving the 6 og dose. In subject C. H., who received the 80 Aig dose, cholecalciferol-'H disappearance was less rapid with an initial half-life of 34 hr. In this subject, cholecalciferol represented 49% of the total plasma radioactivity after 48 hr and 3% after 12 days.
Coincident (Table II) . The semilogarithmic disappearance rate of plasma total radioactivity was identical with that of the polar metabolite ( Fig. 1 and Table II). As shown in Table II , the turnover rate of the polar metabolite was similar in the subject (C. H.) who received the 80 itg dose to the rate observed in the subjects given 6 Ag. Characterization of the polar metabolite. The labeled metabolite eluted in fraction 8 from silicic acid columns exhibited chromatographic and other properties of 25-hydroxycholecalciferol. The methods used to compare the properties of the labeled polar metabolite with those of authentic 25-hydroxycholecalciferol (in addition to silicic acid column chromatography) included TLC, formation of the TMS ether derivative and TLC in two different systems, and saponification and chromatography of the nonsaponifiable lipids. Gel filtration. Gel filtration on Sephadex G-200 was performed with three plasma samples, each containing almost all of its radioactivity as the polar metabolite (see Methods for more details). These experiments provide information about the apparent molecular size of the transport protein for the polar metabolite. The results of a representative experiment are shown in Fig. 2 . An identical elution pattern was obtained in each of five chromatographic runs. In each instance, almost all of the radioactivity was eluted in a peak with an elution volume very close to that of plasma albumin. The center of the peak of radioactvity was consistently found to be eluted very slightly after the center of the plasma albumin peak (see Fig. 2 Preparative polyacrylamide gel electrophoresis. The fractions comprising the 'H-containing peak after gel filtration were combined, and the protein was then subjected to preparative polyacrylamide gel electrophoresis. The fractions comprising the 8H-containing peak after gel filtration (e.g. fractions 50-66 in Fig. 2 ) of the pooled sample from subject C. H. were concentrated by ultrafiltration (Diaflo UM-2 membrane; Amicon Corp., Lexington, Mass.) and dialyzed against water. 8 ml of the concentrated sample containing 10 mg of protein per ml in 5% sucrose was applied to a 9.5 cm high column of 7% acrylamide gel.
The electrophoresis was conducted at a constant voltage of 400 v and approximately 20 ma, with an elution rate of 40 ml/hr. Fractions of 6 ml were collected. Fraction 8t 55 * The samples assayed were derived from a sample of pooled plasma collected from subjects A. B., F. B., and R. H. on the 50th day of the study. The pooled plasma was estimated to contain a total vitamin D activity equivalent to 18 ng of cholecalciferol per ml.
t After silicic acid column chromatography of an extract of whole plasma.
As shown in Fig. 3 , the radioactivity migrated in a single sharp peak with a mobility very slightly greater than that of plasma albumin. In each of three experiments, the peak of radioactivity was found to be mainly located along the leading edge of the albumin peak. The mobility of the 'H-containing peak was distinctly less than that of plasma prealbumin, but considerably more than that of proteins with a-mobility. The fractions containing the proteins with a,-mobility, identified by the fluorescence of retinol-binding protein (24) , contained only 4% of the total radioactivity.
Bioassay. The results of a bioassay study are presented in Table IV . In this experiment, virtually all of the biological activity of whole plasma was recovered after ultracentrifugation at density 1.21, in association with the sedimenting proteins of density greater than 1.21. Slightly more than half of the biological activity of plasma was found in fraction 8 after silicic acid column chromatography of an extract of plasma; the remainder was found in the cholecalciferol-containing fractions (fractions 3 + 4 + 5).
These observations were confirmed in a later experiment using plasma collected from a normal 34 yr old male subject who had not been injected with labeled cholecalciferol. In this subject, the vitamin D activity of an extract of whole plasma was equivalent to 26 ng of cholecalciferol per ml of plasma. After ultracentrifugation, an extract of the proteins with d > 1.21 contained bioactivity equivalent to 21 ng of cholecalciferol per ml of plasma. The compounds recovered in fractions 3 + 4 + 5 and in fraction 8, after silicic acid column chromatography, had bioactivity equivalent to 9 and 11 ng of cholecalciferol per ml of plasma, respectively. J. E. Smith and DeW. S. Goodman 
DISCUSSION
The studies reported here demonstrate that the labeled polar metabolite which appears in plasma after the injection of radioactive vitamin Da has a relatively slow turnover with a half-life of 19.6 +0.6 days. In these studies, four of the five subjects were injected with a small, physiological dose (6 jg) of vitamin D3, which was well within the recommended daily allowance of vitamin D (14) . After injection the labeled vitamin Ds disappeared rapidly from plasma, with an initial halflife of approximately 12 hr. After 7 days, labeled unchanged vitamin Ds represented less than 1% of the circulating radioactivity. Coincident with the disappearance of labeled vitamin D3 a more polar component appeared, with chromatographic and other properties of 25-hydroxycholecalciferol. Most (approximately 92%) of the plasma total radioactivity was represented by this component throughout the later part of the study.
The properties of the labeled polar metabolite were compared directly with those of authentic 25-hydroxycholecalciferol. The labeled metabolite cochromatographed with 25-hydroxycholecalciferol on silicic acid columns and on thin layers of silica gel. The two components also cochromatographed during TLC in two different systems after formation of the TMS ether derivatives. Finally, the labeled polar metabolite was shown to be a nonsaponifiable lipid whose chromatographic properties were not altered by saponification. These findings indicate that the labeled polar metabolite in plasma was either 25-hydroxycholecalciferol itself or an extremely similar compound with properties identical with those of 25-hydroxycholecalciferol in the systems examined (or a mixture of such nearly identical compounds). In view of the demonstrated biological activity of the fraction containing the polar metabolite, it is reasonable to conclude that the labeled polar metabolite was probably 25-hydroxycholecalciferol.
A slow disappearance of plasma total radioactivity, after the injection of labeled vitamin D3 into human subjects, has been reported by Mawer et al. (13) . In contrast with our findings, however, Mawer et al. reported that after the initial rapid disappearance of labeled vitamin Ds from plasma and the appearance of labeled polar metabolites, both the unchanged vitamin D3 and its polar metabolites exhibited a prolonged phase with a slow turnover rate. The half-life of labeled vitamin Ds during this later phase of slow turnover was 18-36 days, while that of plasma total radioactivity was 20-44 days (13) .
The differences between these observations and our own may possibly be explained by the relatively large doses [32] and lysolecithin [33] ) circulate in plasma mainly as part of plasma lipoprotein molecules with hydrated densities of less than 1.21 (23, 34) . Since both cholecalciferol and its 25-hydroxy derivative are sterol derivatives and nonsaponifiable lipid alcohols, the fact that these molecules circulate in association with proteins of density greater than 1.21 provides presumptive evidence for the existence of a specific transport protein (or proteins) for these compounds.
This conclusion is supported by recent studies in our laboratory dealing with the transport of retinol (vitamin A alcohol) in plasma. Beginning with the observation that retinol circulates in plasma in association with proteins of density greater than 1.21, we were able to develop a fractionation sequence for the isolation of retinol-binding protein (RBP), the specific transport protein for plasma vitamin A (24) . RBP has now been characterized to a considerable extent (24, 35, 36 
